Terbinafine for CSA-AKI Prevention
NCT07738328
Acute Kidney Injury, Cardiac Surgical Procedures
Guangzhou, Guangdong, China
View Trial DetailsNCT Number: NCT07295392
To determine whether baseline (day 0; day of diagnosis),day 7 and on discharge serum uromodulin levels help predict clinical outcomes in adult patients with sepsis induced AKI.
Trial opening soon.
Get Notified18 year and older
All sexes
Observational
Sepsis remains a leading cause of morbidity and mortality worldwide, with risk rising as organs failure accumulate, particularly when acute kidney injury (AKI) develops. AKI complicates nearly half of all septic episodes in ICU and is independently associated with poorer short- and long-term outcomes. Current prognostic tools as SOFA score , serum creatinine, urine output, NGAL and KIM-1have limited prognostic value. They often detect injury only after significant damage has occurred.
Uromodulin, the most abundant urinary protein produced by the renal thick ascending limb, is present in small amounts in the circulation. Experimental models reveal that uromodulin deficiency worsens sepsis outcomes, while administration of exogenous uromodulin can reduce mortality . In clinical studies of septic patients, early rises in circulating uromodulin are observed, yet those who go on to develop AKI or die tend to have lower levels at presentation. Genetic analyses, however, have not definitively proven a causal protective role for baseline uromodulin.
It has roles in tubular protection, immune modulation, and infection control, These important physiological functions may translate into valuable prognostic tools that may aid in predicting clinical outcomes. Serum uromodulin may serve as an early indicator of both renal tubular integrity and host defence capacity-qualities not captured by existing markers. Assessing serum uromodulin at time of diagnosis(day 0), day 7 and at time of discharge may predict recovery or progression of AKI. Establishing the prognostic value of uromodulin could enable early risk stratification, guide tailored interventions, and inform clinical decision-making, potentially improving outcomes in sepsis-induced AKI.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: 30 days
To assess whether serum uromodulin levels measured at ICU admission (day 0), day 7, and at ICU discharge can predict AKI outcome (complete renal recovery versus progression to chronic kidney disease), length of ICU stay, and 30-day all-cause mortality in adult patients with sepsis-induced acute kidney injury.
Time frame: From ICU admission to ICU discharge.
Assiut University
Other
Serum Uromodulin Prognostic Value in Sepsis Induced AKI
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07738328
Acute Kidney Injury, Cardiac Surgical Procedures
Guangzhou, Guangdong, China
View Trial DetailsNCT07739290
Acute Kidney Injury, Female Urogenital Diseases
View Trial DetailsNCT07719569
Acute Kidney Injury, Female Urogenital Diseases
Wolverhampton, West Midlands, United Kingdom
View Trial DetailsNCT07718373
Acute Kidney Injury, Female Urogenital Diseases
View Trial Details